本帖最后由 老马 于 2012-1-13 21:20 编辑
' N' B$ m1 e2 `: V' H. _3 k& k) V8 a( M- P" a9 ]" F* `
爱必妥和阿瓦斯丁的比较
: D b* ~) w4 J: j6 T
& ^7 O* R3 A" _& {7 W1 X/ {# uhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ R& d A$ C0 A, f# I# q8 }& \
) v) C" s/ }) Z5 A( M0 |
$ S/ W" }4 i2 Y% I8 B, Ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/% N5 W& r7 _' Z; } N3 E2 F) z
==================================================: H9 V$ x# }+ k% H, l. o. D; R
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6 w e" E* b/ `9 g* `. aPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ c. C4 _ n( I4 q" ?. O0 C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% K8 S- n9 e3 p# `7 f
|
显身卡
; C t5 g% z9 t: G+ E* A3 ^
